Latest:
Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer Management
Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Wolfgang Hiddemann, MD, PhD
Latest:
Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma
Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.
Xavier Bosch, MD, MPH
Latest:
Dr. Bosch Discusses the Importance of the HPV Vaccine
Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, discusses the importance of the HPV vaccine in the prevention of cervical cancer.
Xiaohu Mo MS
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation
Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Xifeng Wu, MD, PhD
Latest:
Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCC
Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).
Xiuhua Zhao MS
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Xiuning Le, MD, PhD
Xiuning Le, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center
Latest:
Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC
Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.
Yadav Sapkota, PhD
Latest:
Impact of Genetic Variant on Stroke Risk in Childhood Cancer Survivors Treated With Cranial Radiation Therapy
Yadav Sapkota, PhD, clinical research scientist at St. Jude Children’s Research Hospital, discusses the relationship between a genetic variant and the risk of stroke in childhood cancer survivors treated with cranial radiation therapy.
Yana Pikman, MD
Latest:
Dr. Pikman on Implications of a Matched Targeted Therapy Approach in Pediatric Leukemia
Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses the implications of a matched targeted therapy approach in pediatric leukemia.
Yara Abdou, MD
Latest:
Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer
The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.
Yardena Samuels, PhD
Latest:
Yardena Samuels on RASA2 as Prognostic Biomarker in Melanoma
Yardena Samuels, PhD, Tenured Associate Professor, Department of Moleular Cell Biology, the Weizmann Institute of Science, Israel, discuses her lab’s discovery of a potential prognostic biomarker in cutaneous sporadic melanoma.
Yasuhiro Funahashi, MD
Latest:
Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC
Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).
Yasuhiro Oki, MD
Latest:
Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review
The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.
Yasushi Goto, MD, PhD
Latest:
Dr Goto on Datopotamab Deruxtecan Plus Pembrolizumab and Chemotherapy in Advanced NSCLC
Yasushi Goto, MD, discusses primary efficacy findings from the phase 1 TROPION-Lung02 trial of datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy in patients with advanced non–small cell lung cancer.